Rick Pazdur, director of the FDA’s Oncology Center of Excellence, has called for fundamental restructuring of the agency following what he describes as significant internal disruption, speaking at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Global Drug Approval Competition Landscape
FDA facing increased pressure from international regulatory agencies, 2024-2026
FDA experience
announcement
opportunity
Source: ASCO 2026, STAT News | Georgian Medical Journal News
FDA Leadership Acknowledges Organizational Challenges
Speaking at ASCO 2026, Pazdur emphasized that the agency should not simply return to previous operational models following recent upheaval. “We’ve had a lot of destruction here, and it doesn’t mean that we have to just go back and say, well, let’s rebuild it as it was,” he stated during the conference presentation.
The comments represent a rare public acknowledgment from senior FDA leadership of internal organizational difficulties. Pazdur, who has led oncology drug approvals for over three decades, suggested the disruption presents an opportunity for meaningful reform rather than restoration of previous structures.
International Competition Drives Reform Urgency
Pazdur specifically highlighted growing competition from international regulatory agencies, particularly from China, as a driving factor for the need to restructure. The competition extends beyond traditional European counterparts to include emerging regulatory powers in Asia.
The FDA’s Oncology Center of Excellence has been at the forefront of accelerated approval pathways and breakthrough therapy designations. Recent health policy developments have emphasized the need for regulatory agility in responding to global pharmaceutical innovation.
Implications for Drug Development and Approval Processes
Industry observers note that restructuring could significantly impact clinical trial approvals and drug development timelines. The agency’s approach to oncology approvals has historically set precedents for other therapeutic areas.
The timing of Pazdur’s comments at ASCO 2026 suggests coordination with broader industry discussions about regulatory modernization. National Institutes of Health leadership has similarly called for enhanced coordination between research funding and regulatory oversight.
The FDA must embrace restructuring rather than restoration following organizational disruption, creating opportunities for enhanced global competitiveness in drug regulation.
— Rick Pazdur, Director, FDA Oncology Center of Excellence (ASCO 2026)
Key takeaways
- Senior FDA leadership publicly acknowledges significant internal organizational disruption
- China’s regulatory competition identified as key driver for FDA reform needs
- Restructuring opportunity presents alternative to simply restoring previous agency operations
Frequently asked questions
What specific changes is the FDA considering in its restructuring?
While Pazdur did not detail specific structural changes, his comments suggest fundamental operational reforms rather than personnel-focused adjustments. The restructuring appears focused on enhancing competitive positioning against international regulatory agencies.
How might FDA restructuring affect drug approval timelines?
Restructuring aimed at improving global competitiveness could potentially streamline approval processes, though specific timeline impacts remain unclear. The FDA’s oncology division has historically led expedited approval innovations.
What role does China play in FDA’s competitive concerns?
Pazdur specifically mentioned China as part of growing international regulatory competition, suggesting Chinese agencies may be attracting pharmaceutical companies for faster or more favorable approval processes. This represents a shift from traditional US-Europe regulatory leadership.
The FDA’s willingness to acknowledge internal challenges and embrace restructuring reflects broader shifts in global pharmaceutical regulation. As international competition intensifies, particularly from Asian regulatory authorities, the agency’s response could reshape drug development strategies worldwide and influence patient access to innovative therapies across multiple therapeutic areas.
Source: STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
